← Back to Screener
Radiopharm Theranostics Limited American Depositary Shares (RADX)
Price$4.68
Value ScoreC
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-20.69%
Price vs S&P 500 (4W)0.29%
VGM Score48.50
Market Capitalization$53.42M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)2.59x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)-30.93%
Net Profit Margin (TTM)-1236.29%
EPS (TTM)$-0.01
10-Day Avg Trading Volume1.94M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.01
ROI (Annual)-81.94%
Gross Margin (Annual)1.08%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)0.14%
ROA (Last FY)-42.44%
Revenue Growth TTM (YoY)116.02%
EBITD / Share (TTM)$-0.01
Operating Margin (TTM)-1283.95%
Cash Flow / Share (Annual)$-0.01
P/B Ratio1.44x
P/B Ratio (Quarterly)1.71x
Net Income / Employee (Annual)$-1,881,737
EV / Revenue (TTM)10.98x
Net Interest Coverage (TTM)-7.52x
ROA (TTM)-50.60%
EPS Incl Extra (Annual)$-0.01
Current Ratio (Annual)2.67x
Quick Ratio (Quarterly)3.01x
3-Month Avg Trading Volume3.00M
52-Week Price Return-13.04%
Revenue / Employee (TTM)$186,408
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)20.48x
Asset Turnover (Annual)0.04x
52-Week High$0.04
EPS Excl Extra (Annual)$-0.01
26-Week Price Return-4.76%
Quick Ratio (Annual)2.67x
13-Week Price Return-9.09%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.01x
Enterprise Value$28.65M
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$186,264
Pretax Margin (Annual)-1052.43%
Cash / Share (Annual)$0.01
3-Month Return Std Dev68.78%
Net Income / Employee (TTM)$-2,304,223
ROE (Last FY)-81.94%
Net Interest Coverage (Annual)-6.86x
EPS Basic Excl Extra (Annual)$-0.01
Receivables Turnover (TTM)0.41x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)0.64x
ROI (TTM)-93.08%
P/S Ratio (TTM)20.47x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)-41.25%
Year-to-Date Return-20.00%
5-Day Price Return-4.76%
EPS Normalized (Annual)$-0.01
ROA (5Y Avg)-328.52%
Net Profit Margin (Annual)-1010.15%
Month-to-Date Return5.26%
EBITD / Share (Annual)$-0.01
Operating Margin (Annual)-1050.63%
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)13.22x
P/B Ratio (Annual)1.16x
Pretax Margin (TTM)-1287.55%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)-18.84%
Beta1.25x
Revenue / Share (TTM)$0.00
ROE (TTM)-93.08%
52-Week Low$0.02
vGradeC
gGradeB
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RADXRadiopharm Theranostics Limited American Depositary Shares | C | B | D | $4.68 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Radiopharm Theranostics is an Australian clinical-stage radiotherapeutics company targeting cancer with approximately four licensed platform technologies. The company develops diagnostic and therapeutic solutions across pre-clinical and clinical development stages.